These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease. Avataneo V; de Nicolò A; Cusato J; Antonucci M; Manca A; Palermiti A; Waitt C; Walimbwa S; Lamorde M; di Perri G; D'Avolio A J Antimicrob Chemother; 2020 Jul; 75(7):1772-1777. PubMed ID: 32361744 [TBL] [Abstract][Full Text] [Related]
4. A Review on Remdesivir: A Possible Promising Agent for the Treatment of COVID-19. Hashemian SM; Farhadi T; Velayati AA Drug Des Devel Ther; 2020; 14():3215-3222. PubMed ID: 32821086 [TBL] [Abstract][Full Text] [Related]
5. Remdesivir: A beacon of hope from Ebola virus disease to COVID-19. Nili A; Farbod A; Neishabouri A; Mozafarihashjin M; Tavakolpour S; Mahmoudi H Rev Med Virol; 2020 Nov; 30(6):1-13. PubMed ID: 33210457 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor. Humeniuk R; Mathias A; Kirby BJ; Lutz JD; Cao H; Osinusi A; Babusis D; Porter D; Wei X; Ling J; Reddy YS; German P Clin Pharmacokinet; 2021 May; 60(5):569-583. PubMed ID: 33782830 [TBL] [Abstract][Full Text] [Related]
7. Remdesivir (GS-5734) in COVID-19 Therapy: The Fourth Chance. Moirangthem DS; Surbala L Curr Drug Targets; 2021; 22(12):1346-1356. PubMed ID: 33267759 [TBL] [Abstract][Full Text] [Related]
8. Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants. Pitts J; Li J; Perry JK; Du Pont V; Riola N; Rodriguez L; Lu X; Kurhade C; Xie X; Camus G; Manhas S; Martin R; Shi PY; Cihlar T; Porter DP; Mo H; Maiorova E; Bilello JP Antimicrob Agents Chemother; 2022 Jun; 66(6):e0022222. PubMed ID: 35532238 [TBL] [Abstract][Full Text] [Related]
9. The development of broad-spectrum antiviral medical countermeasures to treat viral hemorrhagic fevers caused by natural or weaponized virus infections. Hickman MR; Saunders DL; Bigger CA; Kane CD; Iversen PL PLoS Negl Trop Dis; 2022 Mar; 16(3):e0010220. PubMed ID: 35259154 [TBL] [Abstract][Full Text] [Related]
10. Remdesivir for the treatment of COVID 19: review of the pharmacological properties, safety and clinical effectiveness. Mechineni A; Kassab H; Manickam R Expert Opin Drug Saf; 2021 Nov; 20(11):1299-1307. PubMed ID: 34338121 [TBL] [Abstract][Full Text] [Related]
11. Simulation of Remdesivir Pharmacokinetics and Its Drug Interactions. Deb S; Reeves AA J Pharm Pharm Sci; 2021; 24():277-291. PubMed ID: 34107241 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19. Tempestilli M; Caputi P; Avataneo V; Notari S; Forini O; Scorzolini L; Marchioni L; Ascoli Bartoli T; Castilletti C; Lalle E; Capobianchi MR; Nicastri E; D'Avolio A; Ippolito G; Agrati C; J Antimicrob Chemother; 2020 Oct; 75(10):2977-2980. PubMed ID: 32607555 [TBL] [Abstract][Full Text] [Related]
13. Remdesivir: First Approval. Lamb YN Drugs; 2020 Sep; 80(13):1355-1363. PubMed ID: 32870481 [TBL] [Abstract][Full Text] [Related]
14. Remdesivir: A Closer Look at Its Effect in COVID-19 Pandemic. Taha HR; Keewan N; Slati F; Al-Sawalha NA Pharmacology; 2021; 106(9-10):462-468. PubMed ID: 34515227 [TBL] [Abstract][Full Text] [Related]
15. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Wang Y; Zhang D; Du G; Du R; Zhao J; Jin Y; Fu S; Gao L; Cheng Z; Lu Q; Hu Y; Luo G; Wang K; Lu Y; Li H; Wang S; Ruan S; Yang C; Mei C; Wang Y; Ding D; Wu F; Tang X; Ye X; Ye Y; Liu B; Yang J; Yin W; Wang A; Fan G; Zhou F; Liu Z; Gu X; Xu J; Shang L; Zhang Y; Cao L; Guo T; Wan Y; Qin H; Jiang Y; Jaki T; Hayden FG; Horby PW; Cao B; Wang C Lancet; 2020 May; 395(10236):1569-1578. PubMed ID: 32423584 [TBL] [Abstract][Full Text] [Related]
16. Use of remdesivir for patients with Covid-19: a review article. Azevedo TCP; Azevedo PCP; Silveira Filho RN; Carvalho ARVS; Cezarotti Filho ML; Barbosa FT; Sousa-Rodrigues CF; Matos-Rocha TJ; Ramos FWDS Rev Assoc Med Bras (1992); 2020 Jun; 66(6):838-841. PubMed ID: 32696862 [TBL] [Abstract][Full Text] [Related]
17. On the molecular structure of Remdesivir for the treatment of Covid-19. Sheikholeslami SM; Jahanbani A; Shao Z Comput Methods Biomech Biomed Engin; 2021 Jul; 24(9):995-1002. PubMed ID: 33356621 [TBL] [Abstract][Full Text] [Related]
18. A Review on Remdesivir: A Broad-spectrum Antiviral Molecule for Possible COVID-19 Treatment. Khazir J; Maqbool T; Mir BA Mini Rev Med Chem; 2021; 21(17):2530-2543. PubMed ID: 33596800 [TBL] [Abstract][Full Text] [Related]
19. Why Remdesivir Failed: Preclinical Assumptions Overestimate the Clinical Efficacy of Remdesivir for COVID-19 and Ebola. Yan VC; Muller FL Antimicrob Agents Chemother; 2021 Sep; 65(10):e0111721. PubMed ID: 34252308 [TBL] [Abstract][Full Text] [Related]